Novo Nordisk has blamed middlemen in the U.S. healthcare system for the high prices of its top-selling weight-loss drugs Wegovy and Ozempic, following the launch of an investigation into the drugs ...

Generic versions of Ozempic, Wegovy, and Mounjaro flooded into the market via med spas and ... provide brand-name drugs at a more accessible price, but the profits they made from manufacturing ...

The Danish company's CEO countered that Americans with insurance pay much less than the list price. He explained that Ozempic for diabetes is covered by 99 percent of commercial plans, and Wegovy ...

Ozempic/Wegovy is the first drug on HHS's 2025 list of Medicare price negotiations. As the leaders of the pharmaceutical industry boarded their planes to come home from the JP Morgan Healthcare ...

If price is a concern with receiving the brand-name version of Ozempic or Wegovy, there are patient assistance programs offered by Novo Nordisk, the company that makes and produces both medications.